BRPI0919832A2 - inibidores do recptor-3 do fator de crescimento de fibroblasto(fgfr-3) e metodos de tratamento. - Google Patents
inibidores do recptor-3 do fator de crescimento de fibroblasto(fgfr-3) e metodos de tratamento.Info
- Publication number
- BRPI0919832A2 BRPI0919832A2 BRPI0919832A BRPI0919832A BRPI0919832A2 BR PI0919832 A2 BRPI0919832 A2 BR PI0919832A2 BR PI0919832 A BRPI0919832 A BR PI0919832A BR PI0919832 A BRPI0919832 A BR PI0919832A BR PI0919832 A2 BRPI0919832 A2 BR PI0919832A2
- Authority
- BR
- Brazil
- Prior art keywords
- fgfr
- inhibitors
- growth factor
- factor receptor
- fibroblast growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19685508P | 2008-10-20 | 2008-10-20 | |
PCT/US2009/060840 WO2010048026A2 (en) | 2008-10-20 | 2009-10-15 | Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0919832A2 true BRPI0919832A2 (pt) | 2015-12-15 |
BRPI0919832A8 BRPI0919832A8 (pt) | 2019-01-08 |
Family
ID=42062445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0919832A BRPI0919832A8 (pt) | 2008-10-20 | 2009-10-15 | inibidores do recptor-3 do fator de crescimento de fibroblasto (fgfr-3) e métodos de tratamento. |
Country Status (17)
Country | Link |
---|---|
US (3) | US8043618B2 (pt) |
EP (1) | EP2342232A2 (pt) |
JP (1) | JP5577345B2 (pt) |
KR (1) | KR101370798B1 (pt) |
CN (2) | CN103524620A (pt) |
AR (1) | AR073770A1 (pt) |
AU (1) | AU2009307841B2 (pt) |
BR (1) | BRPI0919832A8 (pt) |
CA (1) | CA2741127C (pt) |
EA (1) | EA021584B1 (pt) |
IL (1) | IL211807A0 (pt) |
MX (1) | MX2011004317A (pt) |
NZ (1) | NZ592369A (pt) |
TW (1) | TWI381848B (pt) |
UA (1) | UA101681C2 (pt) |
WO (1) | WO2010048026A2 (pt) |
ZA (1) | ZA201101938B (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR073770A1 (es) * | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
CN104788564A (zh) * | 2009-03-25 | 2015-07-22 | 健泰科生物技术公司 | 抗-fgfr3抗体及其使用方法 |
WO2013088191A1 (en) | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
WO2014111744A1 (en) | 2013-01-16 | 2014-07-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
BR112015021423A2 (pt) | 2013-03-06 | 2017-07-18 | Genentech Inc | métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão |
TWI541022B (zh) | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法 |
AU2015236073B2 (en) | 2014-03-25 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | FGF21 receptor agonists and uses thereof |
WO2015187521A2 (en) * | 2014-06-03 | 2015-12-10 | Merck Sharp & Dohme Corp. | Anti-blys antibodies |
CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
MX366786B (es) * | 2014-09-05 | 2019-07-23 | Hyperfine Res Inc | Metodos y aparato de supresion de ruido. |
CA2976638A1 (en) * | 2015-02-19 | 2016-08-25 | Bioclin Therapeutics, Inc. | Methods, compositions, and kits for treatment of cancer |
EP3265462A1 (en) | 2015-03-03 | 2018-01-10 | INSERM - Institut National de la Santé et de la Recherche Médicale | Fgfr3 antagonists |
TW201711702A (zh) | 2015-06-04 | 2017-04-01 | 應克隆公司 | 使用針對纖維母細胞生長因子受體3(fgfr3)之化合物的療法 |
CA3007644A1 (en) | 2015-12-11 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
KR20220122762A (ko) | 2016-07-07 | 2022-09-02 | 화이자 인코포레이티드 | 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도 |
TW201833140A (zh) * | 2017-01-09 | 2018-09-16 | 美商莫瑞麥克製藥公司 | 抗fgfr抗體及使用方法 |
US11505611B2 (en) | 2020-08-21 | 2022-11-22 | Genzyme Corporation | FGFR3 antibodies and methods of use |
CN114015770B (zh) * | 2021-12-30 | 2022-04-26 | 佛山市第三人民医院(佛山市精神卫生中心) | 精神分裂全外周血rna标志物fgfr3及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
ATE440869T1 (de) * | 2001-06-20 | 2009-09-15 | Fibron Ltd | Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon |
CA2550245A1 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
CA2654502C (en) * | 2006-06-06 | 2015-07-14 | Crucell Holland B.V. | Human binding molecules having killing activity against enterococci and uses thereof |
MY170607A (en) * | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
EP2185719B1 (en) * | 2007-08-02 | 2013-11-13 | NovImmune SA | Anti-rantes antibodies and methods of use thereof |
JP4954326B2 (ja) * | 2008-04-11 | 2012-06-13 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
EP2313435A4 (en) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
AR073770A1 (es) * | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
-
2009
- 2009-10-05 AR ARP090103832A patent/AR073770A1/es unknown
- 2009-10-05 TW TW098133737A patent/TWI381848B/zh not_active IP Right Cessation
- 2009-10-15 KR KR1020117008935A patent/KR101370798B1/ko not_active IP Right Cessation
- 2009-10-15 CN CN201310384769.3A patent/CN103524620A/zh active Pending
- 2009-10-15 AU AU2009307841A patent/AU2009307841B2/en not_active Ceased
- 2009-10-15 CA CA2741127A patent/CA2741127C/en not_active Expired - Fee Related
- 2009-10-15 MX MX2011004317A patent/MX2011004317A/es active IP Right Grant
- 2009-10-15 NZ NZ592369A patent/NZ592369A/xx not_active IP Right Cessation
- 2009-10-15 UA UAA201104814A patent/UA101681C2/ru unknown
- 2009-10-15 JP JP2011532250A patent/JP5577345B2/ja not_active Expired - Fee Related
- 2009-10-15 CN CN200980141656.2A patent/CN102186884B/zh not_active Expired - Fee Related
- 2009-10-15 BR BRPI0919832A patent/BRPI0919832A8/pt not_active IP Right Cessation
- 2009-10-15 EP EP09737319A patent/EP2342232A2/en not_active Ceased
- 2009-10-15 WO PCT/US2009/060840 patent/WO2010048026A2/en active Application Filing
- 2009-10-15 EA EA201170590A patent/EA021584B1/ru not_active IP Right Cessation
- 2009-10-15 US US12/579,825 patent/US8043618B2/en not_active Expired - Fee Related
-
2011
- 2011-03-14 ZA ZA2011/01938A patent/ZA201101938B/en unknown
- 2011-03-17 IL IL211807A patent/IL211807A0/en unknown
- 2011-09-19 US US13/235,900 patent/US8182815B2/en not_active Expired - Fee Related
-
2012
- 2012-04-20 US US13/452,043 patent/US8404240B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2741127A1 (en) | 2010-04-29 |
US8043618B2 (en) | 2011-10-25 |
JP5577345B2 (ja) | 2014-08-20 |
CA2741127C (en) | 2015-06-02 |
JP2012505912A (ja) | 2012-03-08 |
EP2342232A2 (en) | 2011-07-13 |
NZ592369A (en) | 2013-02-22 |
EA021584B1 (ru) | 2015-07-30 |
AU2009307841A1 (en) | 2010-04-29 |
US8182815B2 (en) | 2012-05-22 |
WO2010048026A3 (en) | 2010-07-15 |
AR073770A1 (es) | 2010-12-01 |
WO2010048026A2 (en) | 2010-04-29 |
KR20110056554A (ko) | 2011-05-30 |
US20100098696A1 (en) | 2010-04-22 |
KR101370798B1 (ko) | 2014-03-14 |
IL211807A0 (en) | 2011-06-30 |
AU2009307841B2 (en) | 2013-09-12 |
US20120219563A1 (en) | 2012-08-30 |
MX2011004317A (es) | 2011-06-24 |
UA101681C2 (ru) | 2013-04-25 |
CN103524620A (zh) | 2014-01-22 |
CN102186884B (zh) | 2014-08-13 |
CN102186884A (zh) | 2011-09-14 |
BRPI0919832A8 (pt) | 2019-01-08 |
TWI381848B (zh) | 2013-01-11 |
US20120009200A1 (en) | 2012-01-12 |
ZA201101938B (en) | 2012-08-29 |
US8404240B2 (en) | 2013-03-26 |
TW201026325A (en) | 2010-07-16 |
EA201170590A1 (ru) | 2011-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0919832A2 (pt) | inibidores do recptor-3 do fator de crescimento de fibroblasto(fgfr-3) e metodos de tratamento. | |
DK2376015T3 (da) | Pneumopedisk-ortodontisk instrument, system og fremgangsmåde. | |
BRPI0922440A2 (pt) | dispositivo protético e método de fabricação do mesmo . | |
BRPI0814941A2 (pt) | Composição de tratamentode semente, e, método de tratamento de semente. | |
BRPI0913227A2 (pt) | método, e objeto | |
BRPI0923912A2 (pt) | aparelho de cateter. | |
BRPI0819980A2 (pt) | Conjunto e método de sutura | |
DK2252342T3 (da) | Indretninger og fremgangsmåder til behandling af skadet væv | |
BRPI0910854A2 (pt) | métodos de tratamento | |
BRPI0920406A2 (pt) | dispositivos de terminação e métodos relacionados. | |
BRPI0919575A2 (pt) | método, e, composição | |
FI20080666A (fi) | Ferriittis-austeniittinen ruostumaton teräs | |
BRPI0910925A2 (pt) | conjuntos de transferência de líquido e métodos relacionados | |
BRPI0823277A2 (pt) | Composição, e , método | |
DK2379018T3 (da) | Proteseovertræk | |
DK2344086T3 (da) | Ortopædisk protese | |
DK2330887T3 (da) | Behandlingsindretning | |
BRPI0920527A2 (pt) | método de alinhamento de queimador oval | |
BR112012003151A2 (pt) | composição de revestimento, e, método. | |
BRPI0823238A2 (pt) | Composição, e, método | |
NL1037087A1 (nl) | Interferometer calibration system and method. | |
BR112012005140A2 (pt) | inibidores de hsl úteis no tratamento de diabetes | |
BRPI0907448A2 (pt) | Instrumentos. | |
BRPI0920681A2 (pt) | inibidores de decahidro-1h-indenoquinolinona e decahidro-3h-ciclopentafenantridinona de cyp17 | |
NL2003204A1 (nl) | Lithographic apparatus and method. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2536 DE 13-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |